0 | |
Edward Abrahams President Personalized Medicine Coalition Dr Edward Abrahams is President of the Personalized Medicine Coalition (PMC). Representing innovators, scientists, patients, providers and payers, PMC promotes the understanding and adoption of personalised medicine concepts, services and products for the benefit of patients and the health system. It has grown from its original 18 founding members in 2004 to over 225 today. Previously Dr Abrahams was Executive
Director of the Pennsylvania Biotechnology Association, where he spearheaded
the successful effort that led to the The author of numerous essays, Dr
Abrahams serves on the editorial board of Personalized Medicine and has also
taught history and public policy at
| |
Kofi Amegashie Managing Executive Africa Adcock Ingram Healthcare Kofi Amegashie is Managing
Executive, Africa of Adcock Ingram Healthcare Pty. Ltd with responsibility for
all business operations on the African continent outside Prior to joining Adcock
Ingram Healthcare, Mr Amegashie had over 25 years of business experience. In
2010, he joined the financial services firm, Alexander Forbes Group as Chief
Executive Officer of the Keen to contribute to the growth of business in Africa, Mr Amegashie joined the International Finance Corporation (IFC) in 2002 with responsibility for small and medium enterprise (SME) development in Africa and was seconded to Johannesburg to drive the strategy development for the commercialisation of the Africa Project Development Facility (a multi- donor funded facility that is focused on the sustainable development of SMEs in Africa) and later, in 2003, co-founded a pan-African consulting firm, Strat Afrique, specialising in business strategy development and implementation. Mr Amegashie graduated with a
BSc degree from
| |
Richard Bergström Director General European Association of Pharmaceutical Industries and Associations (EFPIA) Richard Bergström has been
the Director General of the European Federation of Pharmaceutical Industries
and Associations (EFPIA) since April 2011. Previously he served for nine years
as the Director-General of LIF, the Swedish Association of the Pharmaceutical
Industry, following positions in | |
Jacques Bouwens Head, Global Healthcare Russell Reynolds Associates Jacques Bouwens leads the Global
Healthcare sector of Russell Reynolds. He specialises in senior-level executive
and non-executive board assignments in the healthcare and technology
industries. Mr Bouwens has recently authored a broad range of articles covering
leadership strategies. Recent assignments include advising clients on CEO
succession and senior level executive assessments. Most recently he has advised
a number of large multinationals with respect to the appointment of experienced
non-executive directors with specific relevant experience in healthcare.
Prior to joining Russell Reynolds
Associates in 1995, Mr Bouwens served for five years as Director, Human
Resources Europe for St Jude Medical, a global medical technology and services
company. At St Jude, he was responsible for the creation of the company's
European organisation, headquartered in Mr Bouwens received his MS degree in
Social and Organisational Psychology from the State University of Utrecht, the
| |
William Burns Former Chief Executive, Roche Pharmaceuticals and Independent Director on several Boards William Burns has spent all
his career in Pharmaceuticals working for Beecham and then for Roche Pharmaceuticals.
Mr Burns retired from his position as CEO of Roche Pharmaceuticals at the end
of 2009. He is now a non-executive director in several healthcare companies,
notably Roche Holdings (Switzerland); Shire Pharmaceuticals (Ireland); Biotie
Therapeutics (Finland); Chugai (Japan); Vestergaard (Switzerland) and Masters
Pharmaceuticals (UK). He also chairs the Department of Health ( | |
Darren Campili Managing Director, Head of Healthcare Banking EMEA Deutsche Bank Darren Campili is Managing Director, Head of Healthcare Banking EMEA at Deutsche Bank based
in | |
Dr Christopher Corsico Corporate Senior Vice President, Medicine, Quality, Regulatory, Pharmacovigilance and Epidemiology Boehringer Ingelheim Dr Christopher Corsico is
Senior Vice President, Corporate Division Medicine and QRPE (Quality,
Regulatory, Pharmacovigilance and Epidemiology) at Boehringer Ingelheim.
During his tenure at
Boehringer Ingelheim, Dr Corsico has also served as Vice President,
Pharmacovigilance for the Dr Corsico spent two
years at the National Institutes of Health as a Howard Hughes – National Institutes of Health Research Scholar
studying mammalian cell growth regulation prior to receiving his medical degree
from | |
Said Darwazah Chief Executive Officer Hikma Said Darwazah is the Chief Executive
Officer of Hikma Pharmaceuticals PLC, a leading global generic pharmaceutical
manufacturer with operations across the Pharmaceuticals in the Mr Darwazah has a degree in Industrial
Engineering from | |
Nikos Dedes Chair Positive Voice, Greece & Member of the EMA Management Board Nikos Dedes is Founder and Chair of ‘Positive Voice’, the Greek Association of People Living with HIV and Founder and Vice-Chair of ‘Prometheus’, the Hellenic Liver Patient Association. Mr Dedes is a past Chair of the European AIDS Treatment Group (EATG). Currently he is a member of the Management Board of the European Medicines Agency (EMA), a member of the Steering Committee of the European HIV Clinical Trials Network, a member of the HIV Treatment Guidelines Panel of the European AIDS Clinical Society, a member of the Strategic and Technical Advisory Committee for HIV/AIDS at WHO, a member of the DIA Advisory Council of Europe (ACE) and a member of various advisory boards for DG Research projects and at the European Centre for Disease Prevention and Control (ECDC). | |
Dr Marijn Dekkers Chairman of the Board of Management Bayer Dr Marijn Dekkers took over
as Chairman of Bayer AG’s Group Board of Management in October 2010. He is a
member of the Board of Directors of General Electric in the Dr Dekkers began his
professional career in 1985 as a scientist at the corporate research centre of
General Electric in the | |
Eyal Desheh Acting President and CEO Teva Pharmaceutical Industries Eyal Desheh was appointed Acting President and CEO of Teva in October 2013. He has more thirteen years of experience serving in global roles at Teva, first as Deputy Chief Financial Officer from 1989 to 1996, and then returning to take over the role of Group Executive Vice President and Chief Financial Officer in 2008. In these positions, Mr Desheh had responsibility for financial management, information technology, risk management and administration globally. As the longest standing member of Teva’s Executive Committee, he was also highly involved in the development of Teva’s global strategy, announced in 2012. Between his positions at
Teva, Mr Desheh served as Chief Financial Officer and Chief Operating Officer
of Check Point Software Technologies Ltd, an international provider of IT
security products, from 2000 until 2008. Previously he was Chief Financial
Officer of Scitex Ltd, one of Mr Desheh holds a BA in
Economics and an MBA in Finance, both from the | |
Ciarán Devane Chief Executive Macmillan Cancer Support Ciarán Devane is Chief
Executive, Macmillan Cancer Support, a position he assumed in May 2007. Mr
Devane also Co-Chairs the National Cancer Survivorship Initiative and is a
Trustee of the National Council for Voluntary Organisation and the Makaton
Charity. He also serves on the Advisory Council of the Cicely Saunders
Institute. In January 2012, he was appointed as a Non-Executive Director of NHS
England. Previous positions held by Mr Devane include time at Gemini
Consulting, an international management consultancy firm and eight years at
ICI. He has also served as Chairman of a major housing association. He was
educated at
| |
Joan Dzenowagis Senior Scientist-eHealth World Health Organization Joan Dzenowagis is an international health policy specialist at the World Health Organization, with experience in information and communication technology (ICT) and public health, policy and strategy development. Ms Dzenowagis has held posts in disease surveillance, information technology strategy and research, as well as managing an international public-private partnership in ICT and health. Currently she is responsible for eHealth governance, with a focus on national eHealth strategy development, eHealth policy and ethics, and health Internet affairs. | |
Stephen Eck Vice President, Global Head of Medical Oncology Astellas Pharma Global Development Dr Stephen Eck is Vice President and Global Head of Oncology Medical Science at Astellas Pharma Global Development. He is responsible for the oversight of oncology drug development plans. Much of this work is focused on special cancer populations for which unique biology enables the development of personalised cancer therapies. Dr Eck previously served as Vice President, Translational Medicine & Pharmacogenomics at Eli Lilly and Company where he was responsible for the clinical pharmacology components of drug development. His group also developed the biomarkers and companion diagnostics needed for effective decision-making and for tailoring therapeutics to the right patient population. Prior to Joining Lilly, he served in a variety of leadership roles at Pfizer, Inc. Dr Eck is a
Hematologist/Oncologist with broad drug development experience in Oncology and
Neuroscience. He is a Fellow of the American Association for the Advancement of Science and serves on the Scientific
Advisory Board of the ACGT Foundation. He also serves on the Advisory Board of
the | |
Dietmar Eidens Executive Vice President, Human Resources MerckSerono Dietmar Eidens is Executive Vice
President, Human Resources for Merck Serono. He is also a member of the
Pharmaceutical Executive Committee. In 2010, Mr Eidens joined Merck Serono from
F. Hoffmann-LaRoche, where he held various positions in Human Resources,
commencing in 2001, first as Global Head of HR, Pharma Development, and since
July 2005 as Global Head of HR, Pharma Research, Development and Licensing. His
previous professional experience includes senior
global HR positions with GAP, Inc. in Prior to joining GAP, Mr Eidens held HR
positions in the IT/High-Tech industry based in the Mr Eidens is a System Engineer in
Informatics. He holds a Master’s Degree in English, Theology and Educational
Sciences from the University of Mainz, Germany and an MBA from | |
Roberto Gradnik Chief Executive Officer, Stallergenes President, European Biopharmaceutical Enterprises (EBE) Since January 2012 Dr Roberto Gradnik is
Chief Executive Officer of Stallergenes, a European biopharmaceutical company
specialised in the treatment of severe respiratory allergies with allergen
immunotherapy. Trained as a physician, Dr Gradnik has more than 25 years’
experience in the pharmaceutical and biotechnology sector. After holding
various positions with the Knoll Group (a subsidiary of the BASF Group),
including that of Vice-President International Marketing Cardiovascular, he
joined the Serono Group in 1999 as Italy’s General Manager and Head of Southern
European subsidiaries. He was then appointed Executive Vice President for | |
Jane Griffiths Group Chairman Janssen Europe, Middle East and Africa Jane Griffiths is the first female Company Group Chairman of Janssen in EMEA, the pharmaceutical division of the Johnson & Johnson family. She is responsible for this business across the entire region. Her personal approach focuses on sustainability, accountability, openness and collaboration, and she is leading Janssen EMEA to live these values. Ms Griffiths has held a number of senior sales, marketing and R&D positions including International Vice
President for Western Europe and Ms Griffiths holds a PhD
in Biochemistry from the | |
Professor David Haslam, CBE Chair National Institute for Health and Care Excellence (NICE) Professor David Haslam is Chair of the
National Institute for Health and Care Excellence. He is also past-President of the British
Medical Association, past-President of the Royal Professor Haslam was Chairman of Council of the RCGP from 2001 to 2004, and was also a member of the NHS Modernisation Board, Vice Chairman of the Academy of Medical Royal Colleges, a member of the Postgraduate Medical Education Training Board, a member of NHS Medical Education England, and Co-Chair of the MMC Programme Board from 2006 – 2009. He has written 13 books, mainly on health topics for the lay public and translated into 13 languages, and well over a thousand articles for the medical and lay press. He was awarded the CBE in 2004 for services to Medicine and Health Care. | |
John Howe III President and CEO Project Hope
Dr John Howe became President and CEO
of Project HOPE on May 1, 2001. Project HOPE is an international health
education and humanitarian assistance foundation which operates more than 70
programmes in 35 countries on five continents. Before coming to Project HOPE,
Dr Howe held the Distinguished Chair in Health Policy at The University of
Texas Health Science Center at Dr Howe is board certified in both
internal medicine and cardiovascular disease and was a tenured Professor in the
University’s Department of Medicine. He has a Bachelor’s degree from | |
Andrew Jack Pharmaceutical Correspondent Financial Times Andrew Jack has been the
Pharmaceutical Correspondent at the Financial Times since December 2004. Prior
to this he has held a series of posts including accounting and tax correspondent,
Mr Jack is a recent winner of
the Kaiser Family Foundation Global Health Scholarship, and leader of the FT
team that won the Communications Award of the American Society of Tropical
Medicine and Hygiene in 2011. He graduated from | |
Luke Johnson Chairman, Risk Capital Partners Chairman, The Institute of Cancer Research (ICR) Luke
Johnson is Chairman of The Institute of Cancer Research. He is also
Chairman/part owner of Patisserie Valerie and Gail’s bakeries and serves as a
Director at Metro Bank plc. For six years until 2010 he served as Chairman of
Channel 4 Television. He was Chairman of PizzaExpress PLC in the 1990s and
Chairman of Giraffe for nine years until its sale to Tesco in 2013. He
co-founded the largest | |
Dr Jean-Paul Kress President and Chief Executive Officer Sanofi Pasteur MSD Jean-Paul Kress is President of Sanofi Pasteur MSD, a joint European venture between Sanofi Pasteur, the vaccine division of Sanofi, and Merck (known as MSD outside the US and Canada). Sanofi Pasteur MSD is dedicated exclusively to vaccines and develops Sanofi Pasteur's and Merck's vaccines from phase II b onwards for license and marketing in 19 Western European countries. Dr Kress joined the company in 2011. Prior to joining Sanofi
Pasteur MSD, Dr Kress was Vice President and General Manager in Dr Kress holds a MD degree
from Faculté Necker-Enfants Malades in
| |
Dr Denis Lacombe Director European Organisation for Research and Treatment of Cancer (EORTC) Dr Denis Lacombe was appointed as
Director at the European Organisation for Research and Treatment of Cancer
(EORTC) headquarters in November 2010 with mission of ensuring that the
functioning of the headquarters is in line with the decisions of the EORTC
Board and to develop and coordinate the future EORTC Scientific Strategy in
accordance with evolving health care ecosystems. From September 1993 to January
2013 Dr Lacombe worked as Clinical Research Physician at (EORTC) in Dr Lacombe graduated as MD from the
| |
Yann Le Cam Chief Executive Officer, European Organisation for Rare Diseases EURORDIS Yann Le Cam has dedicated 25 years of
professional and personal commitment to health and medical research
non-governmental organisations in Mr Le Cam holds an Executive MBA from
the Hautes Etudes de Commerces – HEC – Jouy-en-Josas
| |
Jeremy Levin Former President and CEO Teva Pharmaceutical Industries Until recently, Dr Levin was the President and CEO of Teva Pharmaceutical Industries Ltd. He is a physician and scientist by training and has worked in the pharmaceutical industry for more than 25 years, building a broad range of relationships with biotech, large pharmaceutical companies and academia. Prior to joining Teva, Dr Levin served on the executive committee of Bristol-Myers Squibb (BMS) and had global responsibilities for strategy, alliances and all transactions. He previously held the position of Global Head of Strategic Alliances at Novartis Institutes of Biomedical Research. In this role, he was the strategic point of contact for worldwide alliances with academia and biotechnology, and also established all strategic collaborations. In 2005 Dr Levin was the
recipient of the Albert Einstein Award for Leadership in Life Sciences and in
2012, FierceBiotech voted him as one of the 25 most influential people in
Biopharma. In November 2013, B’nai B’rith bestowed upon him their Award for Distinguished
Achievement. Dr Levin holds a BA and MA, as well as a doctorate in Cell Biology
and Chromatin Structure from the | |
Reynold W. (Pete) Mooney Global Leader, Life Sciences and Health Care Deloitte Reynold W. (Pete) Mooney is
the Managing Director of the Global Life Sciences and Health Care Industry
Practice of Deloitte Touche Tohmatsu Limited. A corporate strategy consultant
with more than thirty years of experience, his work has been informed by his
experience during his career with several industry segments that have faced
dramatic change. He presently works with his clients to address issues of
global growth, innovation, enterprise restructuring and transformation.
Mr Mooney has extensive
expertise in all areas of business turnaround and restructuring, including work in bankruptcy,
privatisation, and mergers & acquisitions. He gained early exposure to the
pharmaceuticals industry while working with major European chemicals conglomerates in the 1990s
and has worked almost exclusively in the life sciences since then. More
recently, he has focused his attention on healthcare. He works with several
global health systems and private providers, as well as consulting to several
NGOs and not-for-profits in the health education and humanitarian assistance
field. As with many of his clients, he is concerned about healthcare in
underdeveloped economies such as Africa where, for example, he has been working
with a consortium for the Nelson Mandela Children’s Hospital Trust on their
project to build a 300 bed paediatric facility together with the Mr Mooney is presently based
in the | |
Ciaran Murray Chief Executive Officer ICON plc Ciaran Murray is the Chief
Executive Officer of ICON plc. He has 30 years of leadership experience forged
from a career spent operating in global markets in high-growth entrepreneurial
companies and blue-chip multi-nationals, including PwC, Kraft Foods, Novell
Inc. and Northern Foods. He is the Vice-Chairman of the Association of Clinical
Research Organisations (ACRO), which represents the CRO industry globally to
pharmaceutical, biotech and medical device companies, regulators and
legislators, peer associations, academic organisations, patient groups, the
media and the public. Mr Murray graduated with a Bachelor of Commerce degree
from University College Dublin and he is a Fellow of the | |
Lee Newcomer Senior Vice President, Oncology, Genetics and Women’s Health UnitedHealthcare Dr Lee Newcomer is a Senior Vice
President at UnitedHealthcare with strategic responsibility for Oncology,
Genetics and Women’s Health. Dr Newcomer is a board certified medical
oncologist; he practised medical oncology for nine years in Dr Newcomer began his management career
as a Medical Director for CIGNA Health Care of Dr Newcomer earned a BA degree from | |
Daniel O’Day Chief Operating Officer, Pharmaceuticals Roche Daniel O’Day was appointed Chief Operating Officer of the Pharmaceutical Division of Roche in September 2012. Previously, Mr O’Day was the Chief Operating Officer of the Diagnostics Division starting in January 2010. Mr O’Day acquired extensive commercial
experience through diverse roles within Roche worldwide. These began at Roche
Pharma in the Mr O’Day obtained a Bachelor of Science
in Biology from | |
Dr John Parkinson Director Clinical Practice Research Datalink (CPRD) John Parkinson took up the post of Director, Clinical Practice Research Datalink (CPRD), in 2012, having run the General Practice Research Database (GPRD) for the MHRA since 2005. He was also seconded to the Research Capability Programme which came together with GPRD to form the new enlarged observational and interventional data research system. Dr Parkinson gained his PhD
in Biochemistry from the | |
Jörg Reinhardt Chairman of the Board of Directors Novartis Dr Joerg Reinhardt is Chairman of the
Board of Directors for Novartis, a position he assumed in August 2013. Dr
Reinhardt previously served as Chairman of the Board of Management and the Executive Committee
of Bayer HealthCare. Prior to that, he served as Chief Operating Officer of
Novartis from 2008 to 2010, and as Head of the Vaccines and Diagnostics
Division of Novartis from 2006 to 2008. He also served as Chairman of the Board
of the Genomics Institute of the Novartis Research Foundation in the United States from 2000 to 2010; as a member
of the supervisory board of MorphoSys AG in Dr Reinhardt began his career in the
industry at Sandoz Pharma Ltd which he joined in 1982 and held various
positions including Head of Development. Following the merger that created
Novartis in 1996, he became Head of Preclinical Development and Project
Management at Novartis, and assumed the position of Head of Pharmaceutical Development in 1999. He graduated with
a PhD in Pharmaceutical Sciences from | |
Hakan Sakul Executive Director, Head of Diagnostics Worldwide R&D Pfizer Dr Hakan Sakul is currently an
Executive Director in the Development Operations Group of Pfizer where he leads
companion diagnostics efforts across the Worldwide R&D organisation. His
responsibilities also include oversight of Pfizer’s internal Biobank group, and
additionally, he serves as the Development Operations Site Head for Pfizer’s Dr Sakul’s contributions to precision medicine and companion diagnostics have been widely recognised through both internal and external awards, frequent speaking engagements, and press coverage. He is the author of over 30 referred scientific articles as well as many other papers, abstracts and book chapters. Dr Sakul received his BS and MS degrees
from | |
Jonathan Sheldon Global Vice President, Health Sciences Oracle Health Sciences Dr Jonathan Sheldon is
Global Vice President responsible for Oracle’s Health Sciences product
portfolio including the areas of translational medicine and personalised
healthcare. Previously, Dr Sheldon was Chief Scientific Officer at InforSense
(acquired by IDBS), where he was responsible for the company's strategic
direction in the health sciences market, as well as leading the consulting
group responsible for customer implementations. Prior to InforSense, he was
Chief Technology Officer for Confirmant Ltd, where he was responsible for
developing the company's proteomics products and services. He also established
the first bioinformatics group and
was Head of Bioinformatics for five years at Dr Sheldon holds a PhD in
Molecular Biology/Biochemistry from the | |
Rogier Snijdewind Adviser, Responsible Investment PGGM Investment Rogier Snijdewind is an Advisor for
Responsible Investment at PGGM and has been working for PGGM's Responsible
Investment department since January 2008. PGGM currently has around €140bn of
assets under management and is the investment manager of, amongst others, the
pension fund for the Dutch healthcare sector (the second largest pension fund
in the Previously Mr Snijdewind worked for Institutional Shareholder Services and RiskMetrics in various roles. He holds a degree in Public Administration. | |
Pascal Soriot Chief Executive Officer AstraZeneca Pascal Soriot is Chief Executive Officer of AstraZeneca, a
position he assumed in October 2012. Prior to joining AstraZeneca, from 2006 to
2012 Mr Soriot was with Roche Holding
AG, | |
Mike Standing EMEA Industry Leader, Life Sciences and Healthcare Monitor Deloitte Europe Mike
Standing is the Life Sciences and Healthcare industry leader for Deloitte for
EMEA. Mr Standing has consulted to leading pharmaceutical and healthcare
organisations in Europe, US and | |
Dr Miklós Szócska Minister of State for Health, Ministry of Human Resources, Hungary Republic of Hungary Dr Miklós Szócska is Minister
of State for Health at the Ministry of Human Resources of Hungary, a position
he assumed in June 2010. In this role, he is responsible for managing the
overall health sector transformation process in Dr Szócska graduated at
Semmelweis University of Medicine in 1989. He holds a Master of Public
Administration degree from John F. Kennedy School of Government at | |
Professor Sir John Tooke Vice Provost (Health), Head of UCL School of Life & Medical Sciences and Head of UCL Medical School UCL Professor Sir John Tooke is
Vice Provost (Health), Head of the School of Life & Medical Sciences and
Head of the | |
Professor Paul Workman Deputy Chief Executive The Institute of Cancer Research (ICR) Professor Paul Workman is Deputy Chief
Executive of The Institute of Cancer Research (ICR), Professor Workman is a pioneer in the discovery of molecular targeted therapies. He has been closely involved in the discovery of around 20 new cancer drugs, including gefitinib (Iressa) which was approved in lung cancer. He is especially renowned for his innovative research on HSP90 and PI3 kinase inhibitors and as the originator of the widely used Pharmacologic Audit Trail for biomarker-led drug development. He has also been the founder of two biotechnology companies, Piramed Pharma and Chroma Therapeutics and advises many companies and other organisations. Professor Workman was the leader of the ICR/Royal Marsden Hospital Team that won the American Association for Cancer Research Team Science Award in 2012 and he received the 2012 Royal Society of Chemistry World Entrepreneur Award and the Royal Society of Chemistry George & Christine Sosnovsky Award in 2010.
| |
Dr Timothy Wright Global Head, Development Novartis Pharmaceuticals Dr Timothy Wright is Global Head of
Development, Novartis Pharmaceuticals. Prior to this appointment in November
2011, Dr Wright was Senior Vice President and Global Head of Translational
Sciences (TS) at Novartis Institutes for BioMedical Research (NIBR) where his
responsibilities included Translational Medicine, Biomarker Development,
Preclinical Safety (toxicology), and Drug Metabolism and Pharmacokinetics. Dr
Wright joined Novartis in 2004 as Deputy Head of Exploratory Clinical
Development for Translational Research from Pfizer Global Research and
Development as the Exploratory Therapy Area Leader for Inflammation. Before
joining industry, he was Chief of the Division of Rheumatology and Clinical
Immunology at the | |
Dr Feng Zhao Health Division Manager African Development Bank Dr Feng Zhao is the Manager
for the African Development Bank’s health and pharmaceutical operations. Dr
Zhao has more than 25 years of experience in public health, medicine, economics
and demography in Africa and Before he joined the AfDB, Dr
Zhao worked for a range of organisations from World Bank, academia, to
government agencies. His last position was Senior Health Specialist of the
World Bank responsible for both operations and Economic and Sector Work (ESW)
in a number of African countries. From 2009 to 2011, he was based in the World
Bank’s Dr Zhao holds a PhD in
Population and Health Economics from the | |